Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Belzutifan Plus Pembrolizumab in High-Risk ccRCC
NCT07840001Phase 2Not yet recruiting
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Dec 2026
- Primary completion
- Apr 2029
- Countries
- 1
01
Overview
A Phase 2 trial of belzutifan, pembrolizumab in clear cell renal cell carcinoma (ccRCC), sponsored by Peter MacCallum Cancer Centre. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
belzutifanpembrolizumab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT07840001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07840001.